Inovio Pharma (NQ: INO )
12.50 USD +1.92 (+18.15%) Official Closing Price Updated: 7:59 PM EST, Jan 27, 2021 Add to My Watchlist
Press releases about Inovio Pharma
Research Reports Coverage on Biotech Stocks -- Inovio Pharma, Intra-Cellular Therapies, PhaseRx, and Global Blood Therapeutics
February 06, 2017
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the Company will participate in the following upcoming investment conferences:
PCG Advisory Group (PCG) Announces Clients Participating During the 9th Annual Biotech Showcase(TM) Event and the 35th Annual J.P. Morgan Healthcare Conference in San Francisco
December 22, 2016
How These Biotech Stocks are Faring? -- Inovio Pharma, 22nd Century, Omeros, and Cerulean Pharma
December 21, 2016
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced its DNA-based Zika vaccine (GLS-5700) generated robust antigen-specific antibody responses in a first-in-man, multi-center phase I trial. In...
Inovio MERS Vaccine Development to be Expanded with Funding from International Vaccine Institute
December 06, 2016
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the International Vaccine Institute (IVI) will provide new funding and support to further advance GLS-5300, Inovio’s vaccine to prevent...
Inovio Pharmaceuticals Awarded $6.1 Million Sub-grant Through Wistar Institute to Develop DNA-based Monoclonal Antibodies Against Zika Virus
December 01, 2016
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it has been awarded a $6.1 million sub-grant through The Wistar Institute to develop a DNA-based monoclonal antibody designed to provide a...
Inovio’s Co-Founder and Chair of its Scientific Advisory Board Selected as a Top 20 Translational Researcher
November 21, 2016
Dr. David B. Weiner recognized for his innovative medical and scientific research, which has been the basis for over 100 patents
Inovio Wins Deloitte’s “Fast 500” Growth Award
November 16, 2016
Developer of DNA-based Immunotherapies Recognized For its Ability to Attract Grants and Partnerships
Biotech Stocks on Investors' Radar -- Inovio Pharma, Pacific Biosciences of California, BioCryst Pharma, and Sangamo Biosciences
November 14, 2016
Inovio’s Cancer Immunotherapy (INO-3112) Generates T Cell Immune Responses in Tumor Tissue and Peripheral Blood in Patients with HPV-Associated Head and Neck Cancer
November 13, 2016
Four of five study subjects in treated group show progression free survival ranging from nine to 24 months to date in phase I/IIa clinical study
Inovio Pharmaceuticals Zika Vaccine Protects Animals from Infection, Brain Damage and Death
November 10, 2016
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Inovio and its collaborators have published results in Nature Partner Journals (npj) Vaccines demonstrating that its Zika DNA vaccine...
Inovio Pharmaceuticals Reports 2016 Third Quarter Financial Results
November 08, 2016
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the quarter ended September 30, 2016. The following financial results provide a year-over-year comparison of the third...
InvestorsObserver releases covered-call reports for ACADIA Pharmaceuticals, Valero Energy, Kite Pharma, Inovio Pharmaceuticals and Fitbit
November 07, 2016
Inovio Pharmaceuticals to Participate in Upcoming Investment Conferences
November 04, 2016
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the Company will participate at the following upcoming investment conferences:
Inovio Pharmaceuticals to Report Third Quarter 2016 Financial Results November 9, 2016
October 26, 2016
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to discuss its 2016 third quarter financial results and provide a corporate update on...
Inovio Announces FDA Request for Additional Information For Phase III Program; Trial Initiation Delayed
October 24, 2016
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its proposed phase III clinical program for VGX-3100. A clinical...
InvestorsObserver releases covered-call reports for Inovio Pharmaceuticals, Varian Medical Systems, Heron Therapeutics, Chipotle Mexican Grill and Wynn Resorts
October 21, 2016
Inovio CEO Selected As 2016 Healthcare Innovator
October 21, 2016
Inovio Pharmaceuticals, Inc. (NASDAQ:INO), today announced that its President and Chief Executive Officer, Dr. J. Joseph Kim, has been selected as a 2016 Healthcare Innovator by a panel of scientific...
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced strategic leadership appointments to support the advancement of its portfolio of DNA-based cancer immunotherapies and infectious disease...
Learn how to target a 20% return on Tesla Motors, or get option-trade ideas on Intra-Cellular Therapies, Inovio Pharmaceuticals, Universal Display Corporation and Southwestern Energy Company or any st
October 04, 2016
Inovio’s Zika Vaccine Selected As 2016 Technology Breakthrough
September 12, 2016
Popular Mechanics magazine calls Inovio’s Zika prevention a completely new form of vaccination that may be the fastest vaccine ever to come to market
Inovio Pharmaceuticals to Present at Upcoming Investment Conferences
September 01, 2016
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the Company will present a corporate overview at the following upcoming conferences:
Technical Roundup on Biotech Stocks -- Keryx Biopharma, Inovio Pharma, Seattle Genetics, and Arrowhead Pharma
August 30, 2016
Inovio Launches Zika Vaccine Trial in Midst of Puerto Rico Epidemic to Explore Early Signals of Vaccine Efficacy
August 29, 2016
Inovio’s second human Zika vaccine study, a placebo-controlled 160-subject trial, will test for safety, immune responses and initial evidence of efficacy
Inovio Licenses Veterinary Foot and Mouth Disease Vaccine to Plumbline Life Sciences
August 16, 2016
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced it has licensed a veterinary vaccine for foot and mouth disease (FMD) to Plumbline Life Sciences (KONEX: 222670), an animal health company...
Inovio Pharmaceuticals Expands Positive Phase I Ebola Vaccine Trial to Identify Most Optimal Immunization Regimen
August 11, 2016
Further enrollment to also build on safety database for Ebola and SynCon® immunotherapy technology, which has a favorable safety profile to date
GeneOne Life Science Announces Full Enrollment of First-In-Human Study of MERS Vaccine
August 08, 2016
GeneOne Life Science Inc. (KSE:011000) today announced that enrollment has been completed of the first-in-human clinical trial of the GLS-5300 vaccine for MERS (Middle East Respiratory Syndrome) with a...
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the quarter ended June 30, 2016. The following financial results provide a year-over-year comparison of the second quarter...
Inovio Pharmaceuticals Appoints Dr. Ami Shah Brown As Vice President Regulatory Affairs
August 04, 2016
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the appointment of Dr. Ami Shah Brown as Vice President Regulatory Affairs. Dr. Brown, who joined Inovio in 2011 as Senior Director of...